Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVFree Report) in a report released on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

The stock has a market capitalization of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. The firm’s 50 day moving average price is $0.14 and its 200-day moving average price is $0.61. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12.

Institutional Trading of Nabriva Therapeutics

A hedge fund recently raised its stake in Nabriva Therapeutics stock. Renaissance Technologies LLC raised its position in shares of Nabriva Therapeutics plc (NASDAQ:NBRVFree Report) by 102.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 795,938 shares of the biotechnology company’s stock after buying an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.27% of the company’s stock.

About Nabriva Therapeutics

(Get Free Report)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.

See Also

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.